Quarterly report pursuant to Section 13 or 15(d)

Composition of Certain Financial Statement Captions (Details)

v2.4.0.8
Composition of Certain Financial Statement Captions (Details) (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2014
Dec. 31, 2013
Accounts receivable, net    
Accounts receivable $ 24,660 $ 21,652
Less: allowance for doubtful accounts (1,547) (1,885)
Accounts receivable, net 23,113 [1] 19,767 [1]
Inventories, net    
Finished products 12,455 13,374
Work in-process 1,510 1,350
Raw materials 4,948 4,132
Less: inventory reserve (579) (777)
Inventory, net 18,334 [1] 18,079 [1]
Prepaid expense and other assets:    
Prepaid supplies 1,910 945
Prepaid insurance 1,113 892
Pharmsynthez notes receivable 0 6,151
Other receivables 619 1,985
Taxes recoverable 1,298 3,458
Other 2,613 5,653
Prepaid expenses and other current assets 7,553 [1] 19,084 [1]
Intangible assets, net:    
Less: accumulated amortization (29,625) (24,403)
Intangible assets, net 69,059 [1] 74,533 [1]
Accrued expenses:    
Taxes payable 406 702
Deferred revenue 6,393 7,639
Clinical trials 2,616 3,342
Professional fees 1,320 402
Employee benefits 5,405 4,399
Deferred acquisition payments, net of discount 0 5,465
Contingent consideration 24,618 28,047
Other 14,206 15,878
Accrued expenses 54,964 [1] 65,874 [1]
Other long-term liabilities:    
Mortgages and other debts payable 2,948 3,270
Deferred tax liabilities 165,226 166,435
Other, including deferred revenue 2,020 1,509
Other long-term liabilities 218,490 [1] 214,775 [1]
Cytochroma
    
Other long-term liabilities:    
Contingent consideration 37,141 34,401
Farmadiet
    
Other long-term liabilities:    
Contingent consideration 299 504
OPKO Diagnostics
    
Other long-term liabilities:    
Contingent consideration 10,642 8,340
CURNA
    
Other long-term liabilities:    
Contingent consideration 214 316
Technologies
    
Intangible assets, net:    
Intangible assets 53,012 51,660
Customer relationships
    
Intangible assets, net:    
Intangible assets 22,511 22,725
Product registrations
    
Intangible assets, net:    
Intangible assets 9,687 9,692
Tradenames
    
Intangible assets, net:    
Intangible assets 3,615 3,669
Covenants not to compete
    
Intangible assets, net:    
Intangible assets 8,669 8,671
Other
    
Intangible assets, net:    
Intangible assets $ 1,190 $ 2,519
[1] As of June 30, 2014 and December 31, 2013, total assets include $7.7 million and $6.7 million, respectively, and total liabilities include $13.5 million and $10.4 million, respectively, related to SciVac Ltd (“SciVac”), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.